<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808271</url>
  </required_header>
  <id_info>
    <org_study_id>H-20060730</org_study_id>
    <nct_id>NCT04808271</nct_id>
  </id_info>
  <brief_title>The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
  <official_title>The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195&#xD;
      (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant&#xD;
      irritable bowel syndrome (IBS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBS is the most frequently diagnosed gastrointestinal disease and also the most common cause&#xD;
      of referrals to gastroenterology departments in Denmark.&#xD;
&#xD;
      The possibilities for treatment for IBS are limited. Treatment strategies that involve the&#xD;
      microbiota provide symptom relief in some IBS patients. Several studies have demonstrated&#xD;
      that the composition of the gut microbiota in IBS patients is different from healthy&#xD;
      controls.&#xD;
&#xD;
      Probiotic interventions has shown promising results, but it currently remains unknown which&#xD;
      probiotics are effective and which are not.&#xD;
&#xD;
      A new probiotic bacterium, Bifidobacterium breve Bif195 (Bif195) has been identified and has&#xD;
      shown great effects on preventing enteropathy and ulcers on the gut mucosa in healthy&#xD;
      volunteers given acetylsalicylic acid, and thereby Bif195 has also shown a potential in&#xD;
      reducing gut permeability defects. This bacterium has not yet been investigated in IBS&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IBS symptoms from baseline measured by IBS-severity scoring system (IBS-SSS) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>IBS-SSS is a composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life. Each measure is rated from 0 to 100, with total scores ranging from 0 (best) to 500 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life from baseline measured by Irritable Bowel Syndrome-Quality of Life (IBS-QOL) Questionnaire Scores at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The IBS-QoL questionnaire consists of 34 items, each with a 5-point response scale. The 34 items are based on the following eight variables: health worries, food avoidance, body image, dysphoria, interference with activity, social reactions, sexual activity and relationships. The IBS-QoL score will be transformed into a 0-100 scale using the formula: total score = (sum of the items-34/170) ×100. Low score (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in bowel habits at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by frequency/day and Bristol Stool Form Scale. The Bristol Stool Form Scale is divided into seven categories were a low value indicate constipation and a high value indicate diarrhoea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in abdominal pain at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured by a VAS scale from 0-10. 0 = no pain, 10 = worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reported according to IHC-GCP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Bif195 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium breve Bif195</intervention_name>
    <description>1 capsule daily for 8 weeks</description>
    <arm_group_label>Bif195 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule daily for 8 weeks</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with IBS-D defined as more than one-fourth (25%) of bowel movements with&#xD;
             Bristol Stool Scale Types 6-7 and less than one-fourth (25%) with Types 1-2&#xD;
&#xD;
          -  Fulfill Rome IV diagnostic criteria for IBS&#xD;
&#xD;
          -  Moderate to severe disease activity (IBS-SSS ≥175)&#xD;
&#xD;
          -  Able to read and speak Danish&#xD;
&#xD;
          -  Normal colonoscopy (performed within 1 year) if the patient had blood in stool&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other chronic gastro intestinal diseases including lactose intolerance and coeliac&#xD;
             disease&#xD;
&#xD;
          -  Fecal calprotectin ≥50 mg/kg&#xD;
&#xD;
          -  Fecal sample positive for enteropathogenic microorganisms&#xD;
&#xD;
          -  Surgical interventions in the GI region (except for appendectomy, hernia repair,&#xD;
             cholecystectomy and gynecological and urological procedures)&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Medications except birth control pills, hormone supplements, allergies/asthma agents,&#xD;
             blood pressure and cholesterol-lowering agents, proton pump inhibitors and&#xD;
             non-prescription medicines; abnormal colonoscopy findings&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or breastfeeding females&#xD;
&#xD;
          -  Ingestion of probiotics or antibiotics &lt;4 weeks before the inclusion&#xD;
&#xD;
          -  Abnormal screening biochemistry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ida MB Grønbæk, MD</last_name>
    <phone>004530366773</phone>
    <email>ida.marie.bruun.groenbaek@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas M Petersen, MD, PhD</last_name>
    <phone>004538626199</phone>
    <email>andreas.munk.petersen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital, Copenhagen University</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas M Petersen, MD, ph.d</last_name>
      <phone>004538625960</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ida M Grønbæk, MD</last_name>
      <phone>+4538623862</phone>
      <email>andreas.munk.petersen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas M Petersen, MD, ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>andreas m petersen, MD</last_name>
      <phone>+4538625960</phone>
    </contact>
    <contact_backup>
      <last_name>Ida M Grønbæk, MD</last_name>
      <phone>+4538623862</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Munk Petersen</investigator_full_name>
    <investigator_title>Principal Investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

